Multi-Omics for Maternal Health After Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-20

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China

NCT01804751

Preeclampsia

UNKNOWN

Exercise Testing After Preeclampsia

NCT06741436

Preeclampsia Heart Failure Preserved Ejection Fraction Hypertension

RECRUITING

Identifying Biomarkers for Endothelial Dysfunction in Women With Preeclampsia

NCT07084727

Endothelial Function (FMD) Preeclampsia Retinal Vessels

RECRUITING NA

A Novel Multiomic AI Approach for Early Preeclampsia Prediction in Pregnancy

NCT06430398

Preeclampsia

RECRUITING

Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia.

NCT06122220

Pre-Eclampsia

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will recruit and retain a diverse population of pregnant women who are high- and low-risk for hypertensive disorders of pregnancy/preeclampsia (HDP/PE) for longitudinal collection of phenotypic and environmental exposure measures and biosamples for integrative analysis of phenotypic, environmental, and multi-omic data to understand links between development of HDP/PE and associated fetal pathologies during pregnancy, as well as postpartum maternal health. Participation in the study will begin no later than the second trimester of pregnancy (enrollment by 24 weeks of gestation) and continue through the first year postpartum. Over the course of the study, biospecimens and relevant surveys and cardiovascular assessments will be collected at specified intervals/time-points, as outlined in the table below. In-person study visits should take no more than 30 minutes. Relevant medical information collected as part of routine clinical care will be obtained from the electronic medical record (EMR). The study will take place at UCSD and VUMC prenatal clinics and hospital labor and delivery units, or another private location of the participants choosing, such as their home or office.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia Pregnancy Induced Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-risk pregnancy

Pregnant subjects with none of the following: chronic hypertension, pregestational diabetes, renal disease, autoimmune disease, history of preterm preeclampsia in a prior pregnancy

No interventions assigned to this group

High-risk pregnancy

Pregnant subjects with one or more of the following: chronic hypertension, pregestational diabetes, renal disease, autoimmune disease, history of preterm preeclampsia in a prior pregnancy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women 18 years of age to 50 years of age
* 10-24 weeks gestation at time of enrollment
* Singleton pregnancy
* Planning to deliver at a study site (UCSD or VUMC)

Exclusion Criteria

* Inability to give informed consent
* Intrauterine fetal demise
* Fetal genetic or structural anomaly
* Institutionalization for psychiatric disorder, mental deficiency or incarcerated
* Active or history of malignancy requiring major surgery or systemic chemotherapy
* Multi-fetal gestation or a twin demise at any gestational age
* Known maternal or fetal chromosomal anomalies
* Patients who plan to keep their placenta after delivery

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes